Motexafin gadolinium: a promising radiation sensitizer in brain metastasis

Bibliography

• Coalition NABT. Brain Tumor Facts. 2009. Available from: www.nabraintumor.org/facts.html [Cited 19 August 09]
   Google Scholar
• Baisden JM, Benedict SH, Sheng K, Helical TomoTherapy in the treatment of central nervous system metastasis. Neurosurg Focus 2007;22(3):E8
   PubMedGoogle Scholar
• Mehta MP, Tsao MN, Whelan TJ, The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005;63(1):37-46
   PubMed Web of Science ®Google Scholar
• Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol 2004;2(5):405-10, discussion 11-16
   PubMedGoogle Scholar
• Tsao MN, Lloyd N, Wong R, Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869
   PubMedGoogle Scholar
• Patchell RA, Cirrincione C, Thaler HT, Single brain metastases: surgery plus radiation or radiation alone. Neurology 1986;36(4):447-53
   PubMed Web of Science ®Google Scholar
• Andrews DW, Scott CB, Sperduto PW, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665-72
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Regine WF, Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280(17):1485-9
   PubMed Web of Science ®Google Scholar
• States CBTRotU. CBTRUS (2009) statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2005. Hinsdale, IL; 2009
   Google Scholar
• Stummer W, Pichlmeier U, Meinel T, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401
   PubMed Web of Science ®Google Scholar
• Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78(5):767-75
   PubMed Web of Science ®Google Scholar
• Simpson JR, Horton J, Scott C, Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26(2):239-44
   PubMed Web of Science ®Google Scholar
• Walker MD, Green SB, Byar DP, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303(23):1323-9
   PubMed Web of Science ®Google Scholar
• Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978;17(6):475-84
   PubMedGoogle Scholar
• Walker MD, Alexander E Jr, Hunt WE, Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49(3):333-43
   PubMed Web of Science ®Google Scholar
• Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988;22(3):465-73
   PubMed Web of Science ®Google Scholar
• Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5(10):1725-31
   PubMed Web of Science ®Google Scholar
• Chang CH, Horton J, Schoenfeld D, Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52(6):997-1007
   PubMed Web of Science ®Google Scholar
• Nelson DF, Diener-West M, Horton J, Combined modality approach to treatment of malignant gliomas–re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988;(6):279-84
   PubMedGoogle Scholar
• Stupp R, Hegi ME, Mason WP, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745-51
   PubMed Web of Science ®Google Scholar
• Viani GA, Castilho MS, Salvajoli JV, Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 2007;7:53
   PubMed Web of Science ®Google Scholar
• Iliakis G, Kurtzman S. Application of non-hypoxic cell sensitizers in radiobiology and radiotherapy: rationale and future prospects. Int J Radiat Oncol Biol Phys 1989;16(5):1235-41
   PubMed Web of Science ®Google Scholar
• Forouzannia A, Richards GM, Khuntia D, Mehta MP. Motexafin gadolinium: a novel radiosensitizer for brain tumors. Expert Rev Anticancer Ther 2007;7(6):785-94
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25(26):4066-74
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Suh J, RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 2003;21(12):2364-71
   PubMed Web of Science ®Google Scholar
• Scott C, Suh J, Stea B, Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007;30(6):580-7
   PubMed Web of Science ®Google Scholar
• Suh JH, Stea B, Nabid A, Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006;24(1):106-14
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001;11(4):270-80
   PubMed Web of Science ®Google Scholar
• Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14(21):6744-50
   PubMed Web of Science ®Google Scholar
• Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000;59(7):733-9
   PubMed Web of Science ®Google Scholar
• Khuntia D, Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 2004;4(6):981-9
   PubMedGoogle Scholar
• Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5(11):894-902, 7-15
   PubMedGoogle Scholar
• Magda D, Lecane P, Miller RA, Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines. Cancer Res 2005;65(9):3837-45
   PubMed Web of Science ®Google Scholar
• Rodrigus P. Motexafin gadolinium: a possible new radiosensitiser. Expert Opin Investig Drugs 2003;12(7):1205-10
   PubMed Web of Science ®Google Scholar
• Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009;53(1):87-103
   PubMed Web of Science ®Google Scholar
• Evans JP, Xu F, Sirisawad M, Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities. Mol Pharmacol 2007;71(1):193-200
   PubMed Web of Science ®Google Scholar
• Hashemy SI, Ungerstedt JS, Zahedi Avval F, Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 2006;281(16):10691-7
   PubMed Web of Science ®Google Scholar
• Zahedi Avval F, Berndt C, Pramanik A, Holmgren A. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun 2009;379(3):775-9
   PubMed Web of Science ®Google Scholar
• Chen J, Ramos J, Sirisawad M, Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis. Apoptosis 2005;10(5):1131-42
   PubMed Web of Science ®Google Scholar
• Zamzami N, Marchetti P, Castedo M, Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182(2):367-77
   PubMed Web of Science ®Google Scholar
• Waldman T, Zhang Y, Dillehay L, Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3(9):1034-6
   PubMed Web of Science ®Google Scholar
• Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004;16(6):576-80
   PubMed Web of Science ®Google Scholar
• Carde P, Timmerman R, Mehta MP, Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001;19(7):2074-83
   PubMed Web of Science ®Google Scholar
• Young SW, Qing F, Harriman A, Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996;93(13):6610-15
   PubMed Web of Science ®Google Scholar
• Young SW, Woodburn KW, Wright M, Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol 1996;63(6):892-7
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Nurenberg P, Becerra CR, A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999;5(4):739-45
   PubMed Web of Science ®Google Scholar
• Bradley KA, Pollack IF, Reid JM, Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008;10(5):752-8
   PubMed Web of Science ®Google Scholar
• Mehta MP, Rodrigus P, Terhaard CH, Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21(13):2529-36
   PubMed Web of Science ®Google Scholar
• Wu GN, Ford JM, Alger JR. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 2006;77(1):95-103
   PubMed Web of Science ®Google Scholar
• Meyers CA, Smith JA, Bezjak A, Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157-65
   PubMed Web of Science ®Google Scholar
• Mehta MP, Shapiro WR, Phan SC, Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009;73(4):1069-76
   PubMed Web of Science ®Google Scholar
• Ford JM, Seiferheld W, Alger JR, Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007;69(3):831-8
   Google Scholar
• Suh J, Chang E, Timmerman R, Phase II trial of motexafin gadolinium (MGd, Xcytrin) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) [abstract]. Proc Am Soc Clin Oncol 2002;21(13)
   Google Scholar
• Hegi ME, Diserens AC, Gorlia T, MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
   PubMed Web of Science ®Google Scholar
• Evens AM, Spies WG, Helenowski IB, The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res 2009;15(20):6462-71
   PubMed Web of Science ®Google Scholar
• Traynor AM, Thomas JP, Ramanathan RK, Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs 2009
   Web of Science ®Google Scholar
• Lin TS, Naumovski L, Lecane PS, Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(12):1977-82
   PubMed Web of Science ®Google Scholar